Oragenics, Inc. (OGEN) has reported early progress in its Phase IIa clinical trial of ONP-002, a proprietary intranasal neurosteroid being developed for mild traumatic brain injury (mTBI), commonly confirmed that two patients have been enrolled and eight study drug doses administered, marking an important step in the program’s advancement.
